Therapeutic vaccines for the treatment of severe asthma and sever atopic dermatitis in humans and dogs

Purpose and goal

The aim of the Vinnova-project has been to develop a new and highly innovative allergy vaccine and to take it into the clinic. Allergies affect more than 25% of the population in the western world and have thereby become one of the major medical challenges of the 21-century. An effective allergy vaccine could here have the potential of helping these patients and of becoming the base for a new Swedish pharmaceutical company. After several years of complicated developmental work have we now all the components in place to be able to enter clinical trials.

Expected results and effects

We have through a large number of tests in dogs been able to identify and produce vaccine components that gives high antibody titers in dogs and are safe to administrate. We have also tested a new general vaccine component that gives high antibody titers against several targets simultaneously. This component has been patented, which is a prerequisite for future commercializing. We have now reached the point where we can enter clinical trials, which was our aim with the project.

Planned approach and implementation

We have by a rational and systematic procedure developed production and purification methods for the vaccine components and tested these in animals for efficacy and side effects. The vaccine has been shown to give high antibody titers and to be safe to administrate. We have tested a new more general vaccine component that has been patented which is a prerequisite for future commercializing. We have in this project come very far and now reach the point of clinical trials, which was the goal of the project.